PHARMA-TRADE A/S Financials, key figures and credit report
Gross profit — FY 2025
EBIT -44.9 kDKK FY 2025 +45.5% vs 2024
Net debt -1 012.1 kDKK FY 2025 +58% vs 2024
Quick ratio 3 559.5 FY 2025 -209.6 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | |||||
| Costs of management | -57.92 | -17.97 | -42.22 | -82.28 | -44.86 |
| EBIT | -57.92 | -17.97 | -42.22 | -82.28 | -44.86 |
| Other financial income | 111.83 | 231.71 | 2 347.29 | 2 578.74 | 2 653.07 |
| Other financial expenses | -38.08 | -92.15 | -29.59 | - 116.17 | - 186.12 |
| Net income from associates (fin.) | 46 427.96 | 27 921.27 | 32 578.67 | 41 294.46 | 19 363.54 |
| Pre-tax profit | 46 443.79 | 28 042.86 | 34 854.16 | 43 674.75 | 21 785.63 |
| Income taxes | -3.28 | -28.24 | - 500.43 | - 532.56 | - 554.26 |
| Net earnings | 46 440.52 | 28 014.62 | 34 353.72 | 43 142.18 | 21 231.37 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Holdings in group member companies | 228 358.25 | 163 915.86 | 175 436.16 | 194 989.96 | 174 353.50 |
| Investments total | 228 358.25 | 163 915.86 | 175 436.16 | 194 989.96 | 174 353.50 |
| Non-current loans receivable | 428.98 | 571.95 | 562.93 | 550.67 | 483.87 |
| Long term receivables total | 428.98 | 571.95 | 562.93 | 550.67 | 483.87 |
| Inventories total | |||||
| Current amounts owed by group member comp. | 191.32 | 59 701.29 | 61 747.24 | 63 279.53 | 72 150.16 |
| Current other receivables | 6.65 | 4.10 | 5.33 | 16.33 | 0.45 |
| Current deferred tax assets | 14 128.69 | 10 802.40 | 8 709.01 | 11 562.50 | 6 039.68 |
| Short term receivables total | 14 326.65 | 70 507.80 | 70 461.58 | 74 858.36 | 78 190.28 |
| Cash and bank deposits | 3 808.83 | 3 108.61 | 4 943.91 | 2 407.61 | 1 012.08 |
| Cash and cash equivalents | 3 808.83 | 3 108.61 | 4 943.91 | 2 407.61 | 1 012.08 |
| Balance sheet total (assets) | 246 922.70 | 238 104.22 | 251 404.58 | 272 806.60 | 254 039.72 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 3 000.00 | 3 000.00 | 3 000.00 | 3 000.00 | 3 000.00 |
| Shares repurchased | 40 000.00 | 20 000.00 | 30 000.00 | 40 000.00 | 20 000.00 |
| Other reserves | 173 367.95 | 108 925.56 | 120 445.86 | 139 999.66 | 119 363.20 |
| Retained earnings | -20 370.20 | 78 149.04 | 63 585.00 | 46 644.26 | 90 422.90 |
| Profit of the financial year | 46 440.52 | 28 014.62 | 34 353.72 | 43 142.18 | 21 231.37 |
| Shareholders equity total | 242 438.26 | 238 089.22 | 251 384.58 | 272 786.10 | 254 017.47 |
| Non-current liabilities total | |||||
| Current trade creditors | 30.00 | 15.00 | 20.00 | 20.50 | 22.25 |
| Current owed to group member | 4 454.44 | ||||
| Current liabilities total | 4 484.44 | 15.00 | 20.00 | 20.50 | 22.25 |
| Balance sheet total (liabilities) | 246 922.70 | 238 104.22 | 251 404.58 | 272 806.60 | 254 039.72 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 The current price above includes VAT and is paid securely through Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated